Chronic hepatitis C therapy: A rare complication revisited

Mohammed E yad Yaseen Alsabbagh; Naseem Eisa; Abdul H amid Alraiyes; M. Chadi Alraies

doi:10.1136/bcr-2013-200514

Chronic hepatitis C therapy: A rare complication revisited

Mohammed E yad Yaseen Alsabbagh, Naseem Eisa, Abdul H amid Alraiyes, M. Chadi Alraies

Medicine - Cardiology Division

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

The combined regimen of peg-interferon a2a plus ribavirin along with protease inhibitors (boceprevir or telaprevir) is considered as a very portent and effective therapy for hepatitis C infections. However, this combined therapy has been associated with a side effect that can make the course of the disease more complicated. In this case, a 50-year-old man developed insulin-dependent diabetes soon after initiating triple hepatitis C therapy. The treatment had to be stopped and the course of his hepatitis C infection has been challenged with this rare side effect.

Original language	English (US)
Article number	200514
Journal	BMJ case reports
DOIs	https://doi.org/10.1136/bcr-2013-200514
State	Published - Jul 26 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1136/bcr-2013-200514

Find It

Find It at U of M Libraries

Cite this

@article{71e3dbb782394025a4361c2e12b0eb0d,

title = "Chronic hepatitis C therapy: A rare complication revisited",

abstract = "The combined regimen of peg-interferon a2a plus ribavirin along with protease inhibitors (boceprevir or telaprevir) is considered as a very portent and effective therapy for hepatitis C infections. However, this combined therapy has been associated with a side effect that can make the course of the disease more complicated. In this case, a 50-year-old man developed insulin-dependent diabetes soon after initiating triple hepatitis C therapy. The treatment had to be stopped and the course of his hepatitis C infection has been challenged with this rare side effect.",

author = "Alsabbagh, {Mohammed E yad Yaseen} and Naseem Eisa and Alraiyes, {Abdul H amid} and Alraies, {M. Chadi}",

year = "2013",

month = jul,

day = "26",

doi = "10.1136/bcr-2013-200514",

language = "English (US)",

journal = "BMJ case reports",

issn = "1757-790X",

publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Chronic hepatitis C therapy

T2 - A rare complication revisited

AU - Alsabbagh, Mohammed E yad Yaseen

AU - Eisa, Naseem

AU - Alraiyes, Abdul H amid

AU - Alraies, M. Chadi

PY - 2013/7/26

Y1 - 2013/7/26

N2 - The combined regimen of peg-interferon a2a plus ribavirin along with protease inhibitors (boceprevir or telaprevir) is considered as a very portent and effective therapy for hepatitis C infections. However, this combined therapy has been associated with a side effect that can make the course of the disease more complicated. In this case, a 50-year-old man developed insulin-dependent diabetes soon after initiating triple hepatitis C therapy. The treatment had to be stopped and the course of his hepatitis C infection has been challenged with this rare side effect.

AB - The combined regimen of peg-interferon a2a plus ribavirin along with protease inhibitors (boceprevir or telaprevir) is considered as a very portent and effective therapy for hepatitis C infections. However, this combined therapy has been associated with a side effect that can make the course of the disease more complicated. In this case, a 50-year-old man developed insulin-dependent diabetes soon after initiating triple hepatitis C therapy. The treatment had to be stopped and the course of his hepatitis C infection has been challenged with this rare side effect.

UR - http://www.scopus.com/inward/record.url?scp=84882628964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882628964&partnerID=8YFLogxK

U2 - 10.1136/bcr-2013-200514

DO - 10.1136/bcr-2013-200514

M3 - Article

C2 - 23893287

AN - SCOPUS:84882628964

SN - 1757-790X

JO - BMJ case reports

JF - BMJ case reports

M1 - 200514

ER -

Chronic hepatitis C therapy: A rare complication revisited

Abstract

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this